GENFIT Share Price Deutsche Boerse AG
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.40 EUR | +27.62% |
|
+27.83% | +145.19% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 65Cr 74Cr 59Cr 55Cr 105.17Cr 7.05TCr 106.77Cr 714.17Cr 277.63Cr 3.47TCr 277.94Cr 271.97Cr 12TCr | P/E 2025 |
-3.06x | P/E 2026 * | 68.1x |
|---|---|---|---|---|---|
| Enterprise Value | 59Cr 68Cr 54Cr 51Cr 96Cr 6.45TCr 98Cr 653.79Cr 254.16Cr 3.17TCr 254.45Cr 248.98Cr 11TCr | EV / Sales 2025 |
2.34x | EV / Sales 2026 * | 6.31x |
| Free-Float |
86.88% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | +27.52% | ||
| 1 week | +27.83% | ||
| Current month | +22.48% | ||
| 1 month | +49.02% | ||
| 3 months | +71.93% | ||
| 6 months | +123.65% | ||
| Current year | +145.19% |
| 1 week | 10.18 |  | 12.86 |
| 1 month | 8.41 | | 12.86 |
| Current year | 5.08 | | 12.86 |
| 1 year | 3.01 | | 12.86 |
| 3 years | 2.8 | | 12.86 |
| 5 years | 2.74 | | 12.86 |
| 10 years | 2.74 | | 33.76 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +27.62% | +27.83% | - | - | 74Cr | |
| +1.08% | +7.56% | +4.01% | +9.84% | 4.99TCr | |
| +0.79% | -0.79% | +421.13% | +629.39% | 4.02TCr | |
| +0.05% | +7.04% | +27.36% | -4.94% | 3.46TCr | |
| +4.19% | +7.01% | +28.76% | +63.81% | 3.31TCr | |
| -4.19% | +6.03% | +3.76% | +32.17% | 2.75TCr | |
| -1.38% | +2.40% | - | - | 1.7TCr | |
| +0.17% | +4.33% | +74.93% | +138.42% | 1.59TCr | |
| -0.95% | +0.76% | +13.97% | +21.59% | 1.39TCr | |
| +2.43% | +3.69% | +100.25% | +100.35% | 1.35TCr | |
| Average | +2.93% | +5.72% | +84.27% | +123.83% | 2.73TCr | |
| Weighted average by Cap. | +0.43% | +6.43% | +95.73% | +142.16% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 6.68Cr 7.64Cr 6.14Cr 5.72Cr 11Cr 727.73Cr 11Cr 74Cr 29Cr 357.72Cr 29Cr 28Cr 1.23TCr | 9.52Cr 11Cr 8.75Cr 8.15Cr 15Cr 1.04TCr 16Cr 105.03Cr 41Cr 509.66Cr 41Cr 40Cr 1.76TCr |
| Net income | -83.02L -94.97L -76.3L -71.12L -1.35Cr -90Cr -1.37Cr -9.16Cr -3.56Cr -44Cr -3.56Cr -3.49Cr -153.17Cr | 1.86Cr 2.13Cr 1.71Cr 1.6Cr 3.03Cr 202.89Cr 3.07Cr 21Cr 7.99Cr 100Cr 8Cr 7.83Cr 343.66Cr |
| Net Debt | -5.47Cr -6.26Cr -5.03Cr -4.69Cr -8.89Cr -595.99Cr -9.03Cr -60Cr -23Cr -292.96Cr -23Cr -23Cr -1.01TCr | -4.69Cr -5.36Cr -4.31Cr -4.01Cr -7.61Cr -510.46Cr -7.73Cr -52Cr -20Cr -250.92Cr -20Cr -20Cr -864.64Cr |
| Date | Price | Change |
|---|---|---|
| 06/26/06 | €12.86 | +22.48% |
| 03/26/03 | €10.50 | -6.91% |
| 02/26/02 | €11.28 | +6.62% |
| 01/26/01 | €10.58 | +0.76% |
| 30/26/30 | €10.50 | +4.37% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
